We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Longboat Delivery System Could Mean More Powerful Anti-Cancer Drugs

By Biotechdaily staff writers
Posted on 17 Jul 2007
Researchers are reporting the development of carbon nanotubes as a "longboat delivery system” that shows potential for addressing problems that have hindered development of more generally applicable platinum-based anticancer drugs. More...
These include analogues of the widely used and very potent drugs cisplatin, carboplatin, and oxaliplatin.

The study was published in the July 11, 2007, issue of the Journal of the American Chemical Society. The Massachusetts Institute of Technology's (MIT; Cambridge, MA, USA) Dr. Stephen J. Lippard, Ph.D., and Stanford University's (Stanford, CA, USA) Hongjie Dai, Ph.D., and colleagues noted that efforts to produce such molecules have been stalled because the required form of platinum loses activity in the body and becomes ineffective before reaching the tumor. Their answer to this problem was to develop a carbon nanotube delivery system, eventually for delivering platinum compounds safely through the body's biochemical pathways and into the tumor. Once inside the tumor cell, the compounds convert from an inactive form into an active anti-cancer drug.

The chemistry involves attaching platinum compounds to single wall carbon nanotubes (SWNTs), one-atom thick sheets of graphite rolled up into a cylinder with a diameter about 50,000 times smaller than the width of a human hair. The SWNTs act as efficient transporters for the platinum missile, carrying it to the tumor cell and then releasing the platinum as an active drug.

In one experiment with cultured cells, the SWNTs produced platinum levels inside the cells six to eight times higher than those for the platinum unit administered in the conventional way. The longboat SWNTs have the potential to carry other compounds to and into the cancer cell, as demonstrated by the co-delivery of platinum and a fluorescent dye to the cancer cell, which in the future will include tumor-targeting components.


Related Links:
Massachusetts Institute of Technology
Stanford University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.